$15,380.62 consulting Payment -- Gilead Sciences to Dr. Brian Wright

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $15.4K consulting payment to Brian Wright, a HIV Medicine specialist in Camden, NJ. The payment was associated with Ozempic. The payment of $15,380.62 to Dr. Brian Wright from Gilead Sciences for consulting services is a significant amount for a single engagement. The payment is specifically for consulting related to Ozempic, a drug primarily used for diabetes and weight management, which may raise questions given Dr. Wright's specialty. The payment date is in the future (February 5, 2025), indicating this is a reported agreement rather than a completed transaction at the time of reporting.

Patient Guidance: What This Payment Means for You

If you are a patient, discuss any concerns about your doctor's financial relationships with pharmaceutical companies with them directly. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

While consulting fees are common, the substantial amount and the specific drug in relation to the physician's specialty warrant further context compared to typical payments within HIV Medicine.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for consulting services are subject to disclosure under the Sunshine Act, requiring transparency regarding financial relationships between healthcare providers and the industry.

Related Topics

This payment is related to the following healthcare transparency topics:

• cms-open-payments
• pharmaceutical-industry
• physician-compensation
• consulting-fees
• drug-marketing
• ozempic
• gilead-sciences

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $15.4K payment for?

This was a consulting payment of $15.4K from Gilead Sciences to Brian Wright, categorized as "Consulting Fee". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Brian Wright accept pharmaceutical money?

Yes, Brian Wright received this $15.4K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Brian Wright's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $15.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in HIV Medicine?

To compare this payment against HIV Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. HIV Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Brian Wright's relationship with Gilead Sciences?

The payment amount is notably high for a consulting fee. This $15.4K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for HIV Medicine?

There appears to be a potential misalignment between the drug (Ozempic) and the physician's specialty (HIV Medicine).

What should patients do after learning about this payment?

If you are a patient, discuss any concerns about your doctor's financial relationships with pharmaceutical companies with them directly.

What else should I know about this consulting payment?

The payment is categorized as a 'Consulting Fee', suggesting an advisory role.

Related Reports

• View Dr. Brian Wright's full payment report
• Gilead Sciences full spending report
• Browse all HIV Medicine payments
• Browse all payments in New Jersey
• Search for other payments